Literature DB >> 3047163

Defects in beta-cell function and insulin sensitivity in normoglycemic streptozocin-treated baboons: a model of preclinical insulin-dependent diabetes.

D K McCulloch1, P K Raghu, C Johnston, L J Klaff, S E Kahn, J C Beard, W K Ward, E A Benson, D J Koerker, R N Bergman.   

Abstract

During the preclinical period of human insulin-dependent diabetes, both impaired pancreatic beta-cell function and increased insulin resistance are found, although normoglycemia is preserved. To better understand the changes in beta-cell function and insulin sensitivity that occur in preclinical insulin-dependent diabetes, we performed a panel of in vivo beta-cell function tests and measured insulin sensitivity in adolescent male baboons both in normal health and after a small dose of streptozocin which did not induce hyperglycemia. Nine animals were studied before (stage 1) and 1 week after receiving a low dose of streptozocin (stage 2). There was no change in fasting plasma glucose or insulin. The mean glucose disposal rate (Kg) remained within the normal range, but dropped from 2.0 +/- 0.2% +/- SE) to 1.2 +/- 0.1%/min (P less than 0.01), the acute insulin response to arginine (AIR(arg)) fell from 67.7 +/- 19.4 microU/mL (485.8 +/- 139.2 pmol/L) to 32.8 +/- 7.2 microU/mL (235.3 +/- 51.7 pmol/L; P less than 0.05), and the acute insulin response to glucose (AIR(gluc)) fell from 881 +/- 243 microU/mL.10 min (6321 +/- 1744 pmol/L.10 min) to 334 +/- 82 microU/mL.10 min (2396 +/- 588 pmol/L.10 min; P less than 0.01). The most dramatic change, however, was in the ability of hyperglycemia to potentiate AIR(arg) (expressed as the slope of potentiation). This was reduced by 94% from 1.8 +/- 0.5 to 0.1 +/- 0.1 (P less than 0.01), with almost no overlap in values between stages 1 and 2. Insulin sensitivity was also lower 1 week after streptozocin treatment. When the animals were restudied 8 weeks after streptozocin treatment (stage 3) most measures of beta-cell function were not significantly different from those in stage 1. The fasting plasma glucose level was 85.4 +/- 4.3 mg/dL (4.7 +/- 0.2 mmol/L), Kg was 1.8 +/- 0.3%/min, fasting plasma insulin was 35.9 +/- 8.5 microU/mL (257.6 +/- 61.0 pmol/L), AIR(arg) was 67.0 +/- 15.4 microU/mL (480.7 +/- 110.5 pmol/L), and AIR(gluc) was 615.3 +/- 265.3 microU/mL.10 min (4413 +/- 1901 pmol/L.10 min), and tissue insulin sensitivity was 2.7 +/- 0.4 x 10(4) min/microU.mL. These values show extensive overlap with those of stage 1, from which they are not significantly different. The slope of glucose potentiation, however, remained low in all animals at stage 3.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3047163     DOI: 10.1210/jcem-67-4-785

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Dysregulation of insulin secretion in children with congenital hyperinsulinism due to sulfonylurea receptor mutations.

Authors:  A Grimberg; R J Ferry; A Kelly; S Koo-McCoy; K Polonsky; B Glaser; M A Permutt; L Aguilar-Bryan; D Stafford; P S Thornton; L Baker; C A Stanley
Journal:  Diabetes       Date:  2001-02       Impact factor: 9.461

Review 2.  Noninvasive imaging of islet transplantation and rejection.

Authors:  Jason L Gaglia
Journal:  Curr Diab Rep       Date:  2007-08       Impact factor: 4.810

Review 3.  The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality.

Authors:  S E Kahn; S Zraika; K M Utzschneider; R L Hull
Journal:  Diabetologia       Date:  2009-03-27       Impact factor: 10.122

Review 4.  Dynamics of insulin secretion and the clinical implications for obesity and diabetes.

Authors:  Susumu Seino; Tadao Shibasaki; Kohtaro Minami
Journal:  J Clin Invest       Date:  2011-06-01       Impact factor: 14.808

5.  Assessment of β Cell Mass and Function by AIRmax and Intravenous Glucose in High-Risk Subjects for Type 1 Diabetes.

Authors:  Wei Hao; Alyssa Woodwyk; Craig Beam; Henry T Bahnson; Jerry P Palmer; Carla J Greenbaum
Journal:  J Clin Endocrinol Metab       Date:  2017-12-01       Impact factor: 5.958

6.  Comparison of metabolic and neuropathy profiles of rats with streptozotocin-induced overt and moderate insulinopenia.

Authors:  D Romanovsky; J Wang; E D Al-Chaer; J R Stimers; M Dobretsov
Journal:  Neuroscience       Date:  2010-07-01       Impact factor: 3.590

Review 7.  Use and Importance of Nonhuman Primates in Metabolic Disease Research: Current State of the Field.

Authors:  Peter J Havel; Paul Kievit; Anthony G Comuzzie; Andrew A Bremer
Journal:  ILAR J       Date:  2017-12-01

8.  Islet-cell antibodies as predictors of the later development of type 1 (insulin-dependent) diabetes. A study in identical twins.

Authors:  C Johnston; B A Millward; P Hoskins; R D Leslie; G F Bottazzo; D A Pyke
Journal:  Diabetologia       Date:  1989-06       Impact factor: 10.122

9.  Acute insulin response to intravenous glucose, glucagon and arginine in some subjects at risk for type 1 (insulin-dependent) diabetes mellitus.

Authors:  S Bardet; V Rohmer; D Maugendre; M Marre; G Semana; J M Limal; H Allannic; B Charbonnel; P Saï
Journal:  Diabetologia       Date:  1991-09       Impact factor: 10.122

10.  Effect of nicotinic acid-induced insulin resistance on pancreatic B cell function in normal and streptozocin-treated baboons.

Authors:  D K McCulloch; S E Kahn; M W Schwartz; D J Koerker; J P Palmer
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.